Search company, investor...



Series A | Alive

Total Raised


Last Raised

$5M | 13 yrs ago

About Terapio

Terapio is a biopharmaceutical company specializing in the development of a pipeline of therapies based on the transport protein, RLIP76.

Headquarters Location

Austin, Texas, 73301,

United States

Missing: Terapio's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Terapio's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Terapio

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Terapio is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Terapio Patents

Terapio has filed 3 patents.

patents chart

Application Date

Grant Date


Related Topics




Gastrointestinal tract disorders, Rare diseases, Oral mucosal pathology, Inflammations, Conditions of the mucous membranes


Application Date


Grant Date



Related Topics

Gastrointestinal tract disorders, Rare diseases, Oral mucosal pathology, Inflammations, Conditions of the mucous membranes



Latest Terapio News

Austin Technology Incubator Graduates Two Bioscience Companies: Savara Pharmaceuticals and Terapio

Jan 26, 2012

Incubator’s Expertise in Bioscience Grows, Graduates Focus on Biopharmaceuticals Austin, Texas (PRWEB) January 26, 2012 Tonight, at a special graduation and alumni event, the Austin Technology Incubator (ATI), a not-for-profit part of the IC2 Institute of The University of Texas at Austin (UT), will graduate 21 companies. Of those 21, two companies were part of ATI’s Bioscience portfolio: Savara Pharmaceuticals and Terapio. Both have had a tremendous impact on the growing bioscience community in Austin, hiring dozens of workers and raising millions of dollars in funding. Over 20+ years, ATI has developed and refined industry specific capabilities, currently organized into Information Technology, Wireless, Clean Energy and Bioscience sectors. In each industry sector, ATI brings its portfolio companies deep domain expertise, market- and technology-specific networks of advisors and investors. Tonight’s graduation event showcases successes in all four sectors, including two remarkable companies in bioscience. Founded in 2008 in partnership with the City of Austin, ATI-Bioscience works closely with other members of the Central Texas and statewide life science ecosystem, including BioAustin, Central Texas Life Science entrepreneurs, the University of Texas faculty and students and regional hospital and healthcare groups. ATI-Bioscience recently completed a study, supported by the regional community and the Economic Development Administration, to quantitate the need of wet-laboratory space to support life sciences companies in Central Texas. ATI-Bioscience has also partnered with UT’s College of Pharmacy to create an on-campus wet lab facility, UTech Dorm Room, which can be accessed by early-stage life sciences companies in Austin. The ATI-Bioscience hosts symBIOsis, a quarterly educational series, co-sponsored with the Rice Alliance, to bring the entrepreneurial, commercial and academic life sciences communities together. The two Bioscience graduates are: Savara Pharmaceuticals is developing the first inhaled antibiotic for cystic fibrosis (CF) patients targeting the highly contagious "super bug❠Methicillin-Resistant Staphylococcus aureus (MRSA). MRSA is dramatically increasing worldwide. Savara’s Aerovanc has recently completed its first clinical with encouraging results. Terapio is a biopharmaceutical company developing the RLIP76 protein as a medical countermeasure for radiation exposure and chemical threats to civilian, military and first responder populations. The RLIP76 protein works though the oxidative stress pathway and protects as both a prophylactic and post-exposure treatment. Terapio tapped the unique talents and network at ATI to help secure Texas ETF, federal grant and venture capital funding totaling over $7M in less than two years. "We are extremely excited and pleased about our first bioscience graduate companies,❠said Cindy WalkerPeach, PhD, Bioscience Director. "Terapio and Savara are exceptional healthcare-focused companies that will not only have a positive impact on patient care but will favorably impact regional economic growth as well.❠About ATI: The Austin Technology Incubator is a not-for-profit part of the IC2 Institute of The University of Texas at Austin that harnesses business, government and academic resources to provide strategic counsel, operational guidance and infrastructure support to its member companies to help them transition from early stage ventures to successful technology businesses. Since its founding in 1989, ATI has worked with hundreds of companies, helping raise close to $1 Billion in investor capital and creating thousands of jobs in Central Texas. For more information, visit Contact: Laura Beck for ATI laurabeckcahoon(at)gmail(dot)com 512-786-1098 ### For the original version on PRWeb visit: This article (Austin Technology Incubator Graduates Two Bioscience Companies: Savara Pharmaceuticals and Terapio) was originally developed by and is property of American Banking News. Checkout American Banking News for up-to-date banking news and peer to peer lending news.

Terapio Frequently Asked Questions (FAQ)

  • Where is Terapio's headquarters?

    Terapio's headquarters is located at Austin.

  • What is Terapio's latest funding round?

    Terapio's latest funding round is Series A.

  • How much did Terapio raise?

    Terapio raised a total of $5M.

  • Who are the investors of Terapio?

    Investors of Terapio include Sante.

  • Who are Terapio's competitors?

    Competitors of Terapio include Horizon Therapeutics, Arena Pharmaceuticals, Adamas Pharmaceuticals, Eiger BioPharmaceuticals, Pulmatrix and 13 more.

Compare Terapio to Competitors

Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

Can-Fite BioPharma Logo
Can-Fite BioPharma

Can-Fite BioPharma is a biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities.

Cervelo Pharmaceuticals

Cervelo Pharmaceuticals is a semi-virtual clinical development company founded in 2006. The Company is focused on the in-licensing and development of mid stage neurology small molecule drug candidates. It currently has exclusive worldwide rights for all indications to a small molecule, first in class, drug candidate, which has demonstrated a safe and potentially effective capability against neuropathic and inflammatory pain, as well as inflammation.

NeuroMolecular Pharmaceuticals

NeuroMolecular Pharmaceuticals is developing and commercializing superior neuroprotective medicines for the treatment of central nervous system (CNS) disorders. The Company has built a robust pipeline of neuropsychiatric products based upon its scientists' unique understanding of glutamate's central role in mediating CNS disorders. NeuroMolecular is rapidly advancing its next-generation medicines into clinical studies, with preclinical programs underway in depression, pain, Alzheimer's disease, Parkinson's disease, multiple sclerosis and epilepsy. NeuroMolecular is initially focusing on the development of superior derivatives and dosage formulations of memantine, a drug recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease.


Relevare Pharmaceuticals, formerly CNSBio, is a specialty pharmaceutical company focused on the development of novel therapies to treat chronic and acute pain. Relevare Pharmaceuticals exciting clinical-stage pipeline is comprised of programs that combine or reposition drugs known to be active at CNS targets that modulate pain perception and transmission, and for which there is strong safety evidence in humans. In April 2010, CNSBio rebranded to Relevare Pharmaceuticals.

TenX Biopharma

TenX is a biopharmaceutical company focused on late stage development and launch of novel cancer products.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.